{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cognitive+Impairment+Associated+With+Schizophrenia", "query": { "condition": "Cognitive Impairment Associated With Schizophrenia" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 16, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cognitive+Impairment+Associated+With+Schizophrenia&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-07-24T07:33:53.221Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05686239", "title": "A Study to Evaluate RL-007 in the Treatment of Cognitive Impairment Associated With Schizophrenia (CIAS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cognitive Impairment Associated With Schizophrenia (CIAS)", "Cognitive Impairment", "Schizophrenia" ], "interventions": [ { "name": "RL-007 (Inidascamine)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Recognify Life Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 242, "start_date": "2022-12-08", "completion_date": "2025-04-09", "has_results": false, "last_update_posted_date": "2025-07-30", "last_synced_at": "2026-07-24T07:33:53.221Z", "location_count": 20, "location_summary": "Culver City, California • Garden Grove, California • Lafayette, California + 17 more", "locations": [ { "city": "Culver City", "state": "California" }, { "city": "Garden Grove", "state": "California" }, { "city": "Lafayette", "state": "California" }, { "city": "Oceanside", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05686239" }, { "nct_id": "NCT05136690", "title": "Evoked Responses as Pharmacodynamic Biomarkers in Healthy and Schizophrenic Participants (MK-4334-007)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cognitive Impairment Associated With Schizophrenia" ], "interventions": [ { "name": "Nicotine patch", "type": "DRUG" }, { "name": "MK-4334", "type": "DRUG" }, { "name": "Placebo patch", "type": "DRUG" }, { "name": "Placebo capsule", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 38, "start_date": "2022-04-27", "completion_date": "2022-11-04", "has_results": true, "last_update_posted_date": "2024-11-29", "last_synced_at": "2026-07-24T07:33:53.221Z", "location_count": 2, "location_summary": "Long Beach, California • Marlton, New Jersey", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Marlton", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05136690" }, { "nct_id": "NCT02953639", "title": "A Study to Evaluate the Effects of Basmisanil in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) Treated With Antipsychotics", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "Basmisanil", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 214, "start_date": "2016-11-30", "completion_date": "2019-12-12", "has_results": true, "last_update_posted_date": "2021-02-09", "last_synced_at": "2026-07-24T07:33:53.221Z", "location_count": 37, "location_summary": "Little Rock, Arkansas • Rogers, Arkansas • Culver City, California + 32 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Culver City", "state": "California" }, { "city": "Garden Grove", "state": "California" }, { "city": "Glendale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02953639" }, { "nct_id": "NCT01874756", "title": "The Efficacy and Safety of a Selective Estrogen Receptor Beta Agonist (LY500307) for Negative Symptoms and Cognitive Impairment Associated With Schizophrenia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "LY500307 150mg", "type": "DRUG" }, { "name": "LY500307 75mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "LY500307 25mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Indiana University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "MALE", "summary": "18 Years to 65 Years · Male only" }, "enrollment_count": 95, "start_date": "2013-06", "completion_date": "2017-12", "has_results": true, "last_update_posted_date": "2019-07-02", "last_synced_at": "2026-07-24T07:33:53.221Z", "location_count": 4, "location_summary": "Indianapolis, Indiana", "locations": [ { "city": "Indianapolis", "state": "Indiana" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT01874756" }, { "nct_id": "NCT04972227", "title": "Study to Assess the Safety and Pharmacokinetics of CY6463 in Participants With Stable Schizophrenia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "CY6463", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tisento Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 48, "start_date": "2021-09-10", "completion_date": "2022-04-18", "has_results": false, "last_update_posted_date": "2024-08-13", "last_synced_at": "2026-07-24T07:33:53.221Z", "location_count": 2, "location_summary": "Long Beach, California • Marlton, New Jersey", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Marlton", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT04972227" }, { "nct_id": "NCT03745820", "title": "A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cognitive Impairment Associated With Schizophrenia" ], "interventions": [ { "name": "BIIB104", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Biogen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 195, "start_date": "2018-11-15", "completion_date": "2022-04-07", "has_results": true, "last_update_posted_date": "2023-04-18", "last_synced_at": "2026-07-24T07:33:53.221Z", "location_count": 37, "location_summary": "Bentonville, Arkansas • Culver City, California • Garden Grove, California + 31 more", "locations": [ { "city": "Bentonville", "state": "Arkansas" }, { "city": "Culver City", "state": "California" }, { "city": "Garden Grove", "state": "California" }, { "city": "Lemon Grove", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03745820" }, { "nct_id": "NCT01266174", "title": "Effects of Eltoprazine on Cognitive Impairment Associated With Schizophrenia (CIAS) in Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cognitive Impairment", "Schizophrenia" ], "interventions": [ { "name": "Eltoprazine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amarantus BioScience Holdings, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 31, "start_date": "2011-08", "completion_date": "2012-11", "has_results": false, "last_update_posted_date": "2015-04-14", "last_synced_at": "2026-07-24T07:33:53.221Z", "location_count": 6, "location_summary": "Los Angeles, California • Chicago, Illinois • Catonsville, Maryland + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Catonsville", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01266174" }, { "nct_id": "NCT01959594", "title": "A Study To Observe Safety And Blood Concentrations Of PF-06412562 During And Following The Oral Administration Of Multiple Doses Of PF-06412562 In Healthy Adult Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "3 mg PF-06412562", "type": "DRUG" }, { "name": "10 mg PF-06412562", "type": "DRUG" }, { "name": "25 mg PF-06412562", "type": "DRUG" }, { "name": "PF-06412562 TBD mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 40, "start_date": "2013-11", "completion_date": "2014-03", "has_results": false, "last_update_posted_date": "2014-03-28", "last_synced_at": "2026-07-24T07:33:53.221Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT01959594" }, { "nct_id": "NCT00487942", "title": "Efficacy and Safety of Armodafinil as Adjunctive Therapy in Schizophrenic Adults With Cognitive Deficits", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "armodafinil", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cephalon", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 60, "start_date": "2007-07", "completion_date": "2007-12", "has_results": true, "last_update_posted_date": "2013-07-19", "last_synced_at": "2026-07-24T07:33:53.221Z", "location_count": 12, "location_summary": "Garden Grove, California • National City, California • Paramount, California + 9 more", "locations": [ { "city": "Garden Grove", "state": "California" }, { "city": "National City", "state": "California" }, { "city": "Paramount", "state": "California" }, { "city": "Pico Rivera", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00487942" }, { "nct_id": "NCT01911676", "title": "Translational Neuroscience Optimization of GlyT1 Inhibitor", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cognitive Impairments Associated With Schizophrenia" ], "interventions": [ { "name": "PF-03463275", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "21 Years to 65 Years" }, "enrollment_count": 71, "start_date": "2013-08", "completion_date": "2018-12", "has_results": true, "last_update_posted_date": "2024-08-19", "last_synced_at": "2026-07-24T07:33:53.221Z", "location_count": 2, "location_summary": "New Haven, Connecticut • West Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "West Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT01911676" } ] }